Effect of Piceatannol in Human Monocyte-Derived Dendritic Cells In Vitro

Piceatannol is an anti-inflammatory, immunomodulatory, and antiproliferative stilbene that has been shown to interfere with the cytokine signaling pathway. Dendritic cells (DCs) play a pivotal in the initiation of T-cell–mediated immune responses, making them an attractive cellular adjuvant for use...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2005-05, Vol.94 (5), p.974-982
Main Authors: Takei, Masao, Umeyama, Akemi, Arihara, Shigenobu, Matsumoto, Hitoshi
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - pharmacology
Biological and medical sciences
Cell Differentiation - drug effects
Coculture Techniques
Culture Media
Cytokines - metabolism
dendritic cell
Dendritic Cells - drug effects
Fluorescent Antibody Technique
General pharmacology
Humans
Interleukin-12 - metabolism
Lipopolysaccharides - pharmacology
Lymphocyte Culture Test, Mixed
Medical sciences
Monocytes - drug effects
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Phenotype
piceatannol
Platelet Aggregation Inhibitors - pharmacology
Stilbenes - pharmacology
T-Lymphocytes - drug effects
T-Lymphocytes, Helper-Inducer - drug effects
Th1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Piceatannol is an anti-inflammatory, immunomodulatory, and antiproliferative stilbene that has been shown to interfere with the cytokine signaling pathway. Dendritic cells (DCs) play a pivotal in the initiation of T-cell–mediated immune responses, making them an attractive cellular adjuvant for use in cancer vaccines. This study investigated the effect of piceatannol on the phenotypic and functional maturation of human monocyte-derived DCs in vitro. Human monocytes were cultured with GM-CSF and IL-4 for 6days, followed by another 2days in the presence of piceatannol or LPS. DCs harvested on day 8 were examined using functional assays. The expression levels of CD1a, CD80, CD83, and CD86 as expressed by mean fluorescence intensity (MFI) on DCs differentiated from immature DCs after culture with 1 μM of piceatannol for 2days were enhanced and decreased endocytic activity. Piceatannol-treated DCs also displayed enhanced T-cell stimulatory capacity in a MLR, as measured by T-cell proliferation. Similar results were obtained with DCs differentiated with LPS from immature DCs. However, piceatannol did not inhibit phenotypic and functional maturation induced by LPS from immature DCs. Piceatannol-treated DCs induced the differentiation of naive T cells towards a helper T-cell type 1 (Th1) response at DCs/T (1:5) cells ratio depending on IL-12 secretion. These results demonstrate that piceatannol may be used on DC-based vaccine for cancer immunotherapy. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.20279